| Budget Amount *help |
¥24,830,000 (Direct Cost: ¥19,100,000、Indirect Cost: ¥5,730,000)
Fiscal Year 2019: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥7,280,000 (Direct Cost: ¥5,600,000、Indirect Cost: ¥1,680,000)
Fiscal Year 2017: ¥7,540,000 (Direct Cost: ¥5,800,000、Indirect Cost: ¥1,740,000)
Fiscal Year 2016: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
|
|---|
| Outline of Final Research Achievements |
Far-advanced or terminally-ill cancer patients frequently experience difficult symptoms including terminal delirium, refractory pain, nausea and vomiting. However, high-quality clinical evidence for these symptoms are scarce. In this real-world registry study, we indicated safety and effectiveness of the following pharmacological interventions for vulnerable patients with advanced cancer who received palliative care through inpatient palliative care teams, palliative care units, or psycho-oncology services: anti-psychotics administration for terminal delirium; olanzapine for nausea and vomiting; and naldemedine for opioid-induced constipation.
|
